LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

L Mileshkin; T Bochtler; C Pauli; G Durán-Pacheco; C Arslan; F Bigot; N Chalabi; N Cook; A Italiano; F Losa; J Menezes; C Michaud; M Ozguroglu; RAP Cid; JS Ross; KK Shiu; M Stahl; M Thomas; H Moch; A Krämer

doi:10.1016/j.annonc.2023.10.006

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

L Mileshkin, T Bochtler, C Pauli, G Durán-Pacheco, C Arslan, F Bigot, N Chalabi, N Cook, A Italiano, F Losa, J Menezes, C Michaud, M Ozguroglu, RAP Cid, JS Ross, KK Shiu, M Stahl, M Thomas, H Moch, A Krämer

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1254-S1255
Number of pages	2
Journal	Annals of Oncology
Volume	34
Issue number	Supplement 2
DOIs	https://doi.org/10.1016/j.annonc.2023.10.006
Publication status	Published - 20 Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2023.10.006

Cite this

Mileshkin, L., Bochtler, T., Pauli, C., Durán-Pacheco, G., Arslan, C., Bigot, F., Chalabi, N., Cook, N., Italiano, A., Losa, F., Menezes, J., Michaud, C., Ozguroglu, M., Cid, RAP., Ross, JS., Shiu, KK., Stahl, M., Thomas, M., Moch, H., & Krämer, A. (2023). LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology, 34(Supplement 2), S1254-S1255. https://doi.org/10.1016/j.annonc.2023.10.006

Mileshkin, L ; Bochtler, T ; Pauli, C et al. / LBA16 Primary analysis of efficacy and safety in the CUPISCO trial : A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). In: Annals of Oncology. 2023 ; Vol. 34, No. Supplement 2. pp. S1254-S1255.

@article{6b1af90c3aa84412b50025531f7d468e,

title = "LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)",

author = "L Mileshkin and T Bochtler and C Pauli and G Dur{\'a}n-Pacheco and C Arslan and F Bigot and N Chalabi and N Cook and A Italiano and F Losa and J Menezes and C Michaud and M Ozguroglu and RAP Cid and JS Ross and KK Shiu and M Stahl and M Thomas and H Moch and A Kr{\"a}mer",

year = "2023",

month = oct,

day = "20",

doi = "10.1016/j.annonc.2023.10.006",

language = "English",

volume = "34",

pages = "S1254--S1255",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "Supplement 2",

}

Mileshkin, L, Bochtler, T, Pauli, C, Durán-Pacheco, G, Arslan, C, Bigot, F, Chalabi, N, Cook, N, Italiano, A, Losa, F, Menezes, J, Michaud, C, Ozguroglu, M, Cid, RAP, Ross, JS, Shiu, KK, Stahl, M, Thomas, M, Moch, H & Krämer, A 2023, 'LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)', Annals of Oncology, vol. 34, no. Supplement 2, pp. S1254-S1255. https://doi.org/10.1016/j.annonc.2023.10.006

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). / Mileshkin, L; Bochtler, T; Pauli, C et al.
In: Annals of Oncology, Vol. 34, No. Supplement 2, 20.10.2023, p. S1254-S1255.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - LBA16 Primary analysis of efficacy and safety in the CUPISCO trial

T2 - A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

AU - Mileshkin, L

AU - Bochtler, T

AU - Pauli, C

AU - Durán-Pacheco, G

AU - Arslan, C

AU - Bigot, F

AU - Chalabi, N

AU - Cook, N

AU - Italiano, A

AU - Losa, F

AU - Menezes, J

AU - Michaud, C

AU - Ozguroglu, M

AU - Cid, RAP

AU - Ross, JS

AU - Shiu, KK

AU - Stahl, M

AU - Thomas, M

AU - Moch, H

AU - Krämer, A

PY - 2023/10/20

Y1 - 2023/10/20

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001087480203493&DestLinkType=FullRecord&DestApp=WOS

UR - https://www.mendeley.com/catalogue/bde424b9-f8fb-3ada-b2db-6ee76598d52a/

U2 - 10.1016/j.annonc.2023.10.006

DO - 10.1016/j.annonc.2023.10.006

M3 - Meeting Abstract

SN - 0923-7534

VL - 34

SP - S1254-S1255

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 2

ER -

Mileshkin L, Bochtler T, Pauli C, Durán-Pacheco G, Arslan C, Bigot F et al. LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP). Annals of Oncology. 2023 Oct 20;34(Supplement 2):S1254-S1255. doi: 10.1016/j.annonc.2023.10.006

LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

UN SDGs

Access to Document

Other files and links

Cite this